Kairos Pharma, Ltd. · AMEX:KAPA
Kairos Pharma — Investor Presentation (May 2026)
32 slides from Kairos Pharma's investor presentation, May 18, 2026
Slide 1: Kairos Pharma Investor Presentation
KAIROS & PHARMA INVESTOR PRESENTATION NYSE American: KAPA kairospharma.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS KAIROS PHARMA This presentation may contain “forward-looking statements” regarding the current expectations and projections about future events of Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”). “Forward-looking statements” (statements as to matters other than hist
Slide 3: Our Mission
OUR MISSION Kurs Kairos Pharma is dedicated to advancing therapies to overcome critical challenges in cancer drug resistance and immune suppression.
Slide 4: Kairos Highlights
KAIROS HIGHLIGHTS The Problem: Drug Resistance develops for even blockbuster drugs, reducing their effectiveness over time The Solution: CD105 is elevated with resistance. Kairos’ lead candidate ENV 105 reverses resistance for hormone therapy and EGFR targeted therapy for prostate and lung cancer. K
Slide 5: Kairos Investment Highlights
KAIROS INVESTMENT HIGHLIGHTS K KAIROS | Three clinical programs already in progress ENV 105 ¢ Phase 2 trial treating castrate resistant prostate cancer INNOVATIVE CANCER * Phase 1 trial treating EGFR-driven Lung Cancer THERAPEUTICS KROS 201 * immunotherapy cleared IND for glioblastoma New technologi
Slide 6: Portfolio of Innovative Drugs
PORTFOLIO OF INNOVATIVE DRUGS KAIROS US Market Antibody targeting CD105 to reverseresistance toanti- Prostate androgen drugs cancer i = p- $6.5B ENV-105 Antibody targeting CD105 to reverse resistance to EGFR-driven $2B EGFR targeted drugs lung cancer Activated , Teall therapy Steblesoms 0 $3.6B Smal
Slide 7: ENV105: Overcoming Cancer Drug Resistance
ENV105 OVERCOMING CANCER DRUG RESISTANCE K PHARMA Prostate Anti-androgen drugs EGFR drugs (enzalutamide, (osimertinib, abiraterone, apalutamide) erlotinib, gefitinib) development of resistance (CD105) TGFR ~TeRI = vocbea ars BMP4 a ALK1 L de-differentiation THE PROBLEM: Resistance As cancers become
Slide 8: ENV105 restores sensitivity to hormone therapy
ENV105 restores sensitivity to hormone therapy Targets CD105-mediated PROSTATE CANCER castrate resistance K PHARMA ENV105 kills cancer cells resistant to AR Tx (H&E stain in PDX model) More differentiated smaller tumors A” he ie ENV105 inhibits the creation of the AR splice variant which has resista
Slide 9: ENV105 in Prostate Cancer: Randomized Phase 2 Trial
ENV105 K KAIROS IN PROSTATE CANCER PRESENT RANDOMIZED PHASE 2 TRIAL: NCT03418324 Apalutamide with or without ENV105 xtend treat t with 7 z lupron @.... “combination therapy @-@ apalutamide single agent enzalutamide @.... . for compassionate use > [@-@ apalutamide + ENV105 abiraterone @.s.« wee Prost
Slide 10: Phase 1 Patient Summary NCT05534646
Phase 2 Patient Summary NCT05534646 Apalutamide and ENV105 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patient ID 001 002 003 004 005 006 007 008 009 010 Age at enrollment 68 76 73 82 60 68 79 71 69 85 Pre-treatment PSA 7.59 278.55 32.35 59.03 4.49 278.43 5.63 3.37 20.59 0.8
Slide 11: Radiographic PFS points of reference
Radiographic PFS points of reference CARD Trial ARPI-switch median PFS = 3.7 months Cabaxitaxel median PFS = 8 months N= 255 1004 90+ ia 2% 0) 2 28 s 2 ge e: SE 505 F §3 5 Cabazitaxel 22 Sg 405 a3 8 2 § 304 Androgen- é 22 4 signaling— (a targeted 10+ inhibitor Number at risk ——_1— T 1 T (number cens
Slide 12: Progression Free Survival NCT05534646
KAIROS Progression Free Survival NCT05534646 Ke mii Weeks = NR wo > a aD pa! o o o o o o oO oO o o > still on trial @) Unrelated withdrawal Median PFS = 13.7 months* (59 weeks) * Patients continue to be evaluated
Slide 13: Partnering ENV105 for synergy
Partnering ENV105 for synergy K PHARMA ENV-105 and radiation combination shows increased efficacy in a metastatic mouse model B Subcutaneous Tumor Volume 5Gyx2 endpoint graft © 2] 3000: -e IgG e —® ENV105 E 2000 -e- Radiation e -® Combination g 5 1000 e alge | Preclinical collaboration 0 Combining E
Slide 14: ENV105 supporting EGFR-driven lung cancer patients
ENV105 K Es, SUPPORTING EGFR-DRIVEN LUNG CANCER PATIENTS — In Phase | NON-SMALL CELL LUNG CANCER BECOMES RESISTANT TO OSIMERTINIB (TAGRISSO) Overall survival N=44 Log rank test P = 0.0265 == Low CD105 exp. == High CD105 exp] 100) 50 Probability of Survival 50 100 150 200 Months elapsed Tagrisso OSIM
Slide 15: ENV105 in EGFR-Driven Lung Cancer
ENV105 in EGFR-Driven Lung Cancer K KAIROS PHARMA Lung Cancer AstraZeneca’s EGFR inhibitor Tagrisso ($7B in 2024 sales) offers only a partial response in 80% of patients O CD105 is elevated with Tagrisso treatment Preclinical models show ENV105 can overcome resistance and Tagrisso shrink tumors gion
Slide 16: ENV105 in Lung Cancer: NCT05401110
ENV105 IN LUNG CANCER: NCT05401110 PHASE 1 TRIAL FOR EGFR-DRIVEN LUNG CANCER: Osimertinib (Tagrisso) + ENV105 Patients that have become Lung resistant to Tagrisso Cancer N= 9-20 Patients that are incompletely treated Ale Safety lead-in with Tagrisso C) Bayesian design N=20 (persistent ctDNA) PRIMARY
Slide 17: Clinical Trials
PHARMA Clinical Trials K KAIROS Cedars-Sinai Medical Center Maye clue CRO consortium leveraging the the efficiencies of each Centralized regulatory Stanford . . . gee institute to achieve 40 day oversight and institutional Vanderbilt clinical trial activation investigator-initiated trials (June 1, 2
Slide 18: Current Non-dilutive funding
Current Non-dilutive funding KAIROS PHARMA Prostate $3.2M (NCI) ENV105 prostate cancer companion wo biomarker validation v4 $2.4M (Donor) ENV105 lung cancer preclinical and Lung phase 1 trial Ain $1.8M (DOD) ENV105 lung cancer companion 6 ) biomarker identification - Cachexia $0.6M (DOD) ENV205 cach
Slide 19: New Assets Addressing Resistance Mechanisms
New Assets Addressing Resistance Mechanisms K KAIROS PHARMA EGFR-family receptors and MET converge on PI3K— OrbiMed aipcege . Healthcare Fund Management AKT, MAPK, and STAT pathways. Inhibition of one axis often leads to compensatory signaling through the other. HGF EGF,HER2,HER3 MET amplification o
Slide 20: KROS-741 Best in class cMET inhibitor
Kinase C inil [__kROS-741 Best in class cMET inhibitor — KROS-741 MET MET_D1228A MET_D1228G MET_D1228H + MET_D1228Y Total plasma concentration needed 40 ng/mL 525 ng/mL 26,600 ng/mL Fei L MET_F12001 to cover c-Met WT ECso (3.2 nM)! (19.2 nM)! (53.3 nM)? MET_G1163R MET_H1094L Clinical daily dose 400
Slide 21: Best in class cMET inhibitor — KROS-741
Best in class cMET inhibitor — KROS-741 KAIROS PHARMA A: Exon 14 Skipping B: Amplification ® Impaired protein degradation - Ligand-independent dimerization. Node Color se f TL clinically validated in NSCLC with Focal amplifications are more © Target approved Type Ib inhibitors. likely to be drivers
Slide 22: cMET inhibitor — KROS-741 trial design
cMET inhibitor — KROS-741 trial design KAIROS K PHARMA Phase 1 Objectives: Dose finding for optimal dose — RP2D and initial indication determination KROS-741 Phase 1 trial: METAL-1) METAL-1LE N=10 METAL-1A METAL-1LN > RP2D TOX METAL-1EG PK/PD -——> N~16 " N=10 6a 2» Phase 2 trial: METAL-2 potential M
Slide 23: KROS Drug Candidates: Overcoming Immune Suppression
KROS DRUG CANDIDATES K KAIROS OVERCOMING IMMUNE SUPPRESSION Immunotherapy is a $118b market with only a 17% response rate. THE PROBLEM: Cancer is comprised of billions of growing cells. However, our immune system seldom generates enough T cells to kill all the cancer cells. THE SOLUTION: KROS drug c
Slide 24: Targeting GITR to regulate T cell numbers
PHARMA Targeting GITR to regulate T cell numbers K KAIROS ¢ KROS101 targets the GITR ligand and enables T cells to increase in numbers and kill cancer cells more effectively ¢ By increasing T cell numbers and function KROS101 may complement checkpoint inhibitors @™ PBMC 150: @™ PBMC+KROS 101(25uM) +
Slide 25: KROS reduces tumor growth and improves survival in murine models
KROS 101 reduces tumor growth and improves survival in murine tumor models. (A) Representative IVIS images of B16-F10-LUC2 tumor-bearing mice treated with PBS or KROS 101 at the indicated time points. (B) Mean tumor K AIROS KAI volume of B16-F10-LUC2 tumors measured by caliper. (C) Kaplan—Meier surv
Slide 26: KROS102 GITR Antagonist
KROS102 GITRANTAGONIST — Imm§pnity by Teffect&k/Treg K KAIROS, * KROS102: GITR antagonist that decreases T cell numbers and ivi Kairos identified structure of GITR activity. ligand through X ray crystallography. PNAS 2008 * KROS-102 has been shown to decrease T effector cells (killer T cells) and in
Slide 27: Strong Intellectual Property Foundation
STRONG INTELLECTUAL PROPERTY FOUNDATION K KAIROS PHARMA IP extends to 2040 & Exclusive, worldwide rights to IP licensed from Cedars Sinai Medical Center Key IP generated from Murali, Published patents Bhowmick and Yu labs executed internationally KROS301 KROS401 ENV105 KROS101 KROS201 PcT/Us2019/045
Slide 28: Leading Team
LEADING TEAM KAIROS PHARMA John S. Yu, MD Ramchandran Murali, Ph.D ei) Vp, RESEARCH AND DEVELOPMENT CEO & CHAIRMAN Professor, Biomedical Sciences and Research in Immunology at Professor of Neurosurgery, Director Surgical Neuro-Oncology at Penn/Cedars-Sinai Medical Center, Cedars-Sinai Medical Center
Slide 29: Independent Directors
INDEPENDENT DIRECTORS Rahul Singhvi, Sc.D. Chemical engineering from MIT. MBA from the Wharton School of the , University of Pennsylvania, where he graduated as a Palmer Scholar. : Global leader in the Life Sciences industry and is cofounder of the biomanufacturing company, Resilience (National Resi
Slide 30: Kairos Pharma Summary
Kairos Pharma SUMMARY K KAIROS PHARMA Clinical stage company with an antibody that impacts a central mechanism of CANCER DRUG RESISTANCE Extensive pipeline targets IIMIMUNE SUPPRESSION * Enrolling in phase 1 and 2 trials with interim efficacy data in 2025, 2026 Strategic relationship with Cedars-Sin
Slide 31: Kairos Pharma Catalysts
Kairos Pharma CATALYSTS ¢ PARTNERING ADVANCES Research collaboration with major pharmaceutical SECOND QUARTER 2026 ¢ PHASE 1 TRIAL FOR LUNG CANCER Safety data and interim efficacy SECOND QUARTER 2026 ¢ PHASE 2 TRIAL FOR PROSTATE CANCER Efficacy update THIRD QUARTER 2026 ¢ IND FOR KROS 741 CMET INHIB
Slide 32: Investor Relations
KAIROS Y PHARMA INVESTOR RELATIONS CorelR Investors@kairospharma.com NYSE American: KAPA kairospharma.com